Wall Street analysts predict that Integra LifeSciences Holdings Co. (NASDAQ:IART) will post $374.48 million in sales for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Integra LifeSciences’ earnings. The highest sales estimate is $376.70 million and the lowest is $371.31 million. Integra LifeSciences reported sales of $258.67 million in the same quarter last year, which would indicate a positive year over year growth rate of 44.8%. The company is scheduled to report its next quarterly earnings results on Monday, August 9th.
On average, analysts expect that Integra LifeSciences will report full year sales of $1.53 billion for the current financial year. For the next fiscal year, analysts anticipate that the firm will report sales of $1.62 billion, with estimates ranging from $1.61 billion to $1.64 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that follow Integra LifeSciences.
Integra LifeSciences (NASDAQ:IART) last released its earnings results on Tuesday, April 27th. The life sciences company reported $0.69 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.57 by $0.12. Integra LifeSciences had a return on equity of 14.26% and a net margin of 4.10%. The firm had revenue of $360.10 million for the quarter, compared to the consensus estimate of $349.78 million. During the same period in the prior year, the business posted $0.48 earnings per share. The firm’s revenue for the quarter was up 1.6% compared to the same quarter last year.
Several research firms recently weighed in on IART. BTIG Research increased their target price on Integra LifeSciences from $66.00 to $72.00 and gave the stock a “buy” rating in a research report on Tuesday, January 19th. Truist Financial raised their price objective on Integra LifeSciences from $60.00 to $70.00 in a report on Wednesday, January 6th. Credit Suisse Group raised their price objective on Integra LifeSciences from $73.00 to $79.00 and gave the stock an “outperform” rating in a report on Thursday, February 25th. Citigroup raised their price objective on Integra LifeSciences from $70.00 to $78.00 in a report on Thursday, April 29th. Finally, Wells Fargo & Company raised their price objective on Integra LifeSciences from $68.00 to $74.00 and gave the stock an “equal weight” rating in a report on Thursday, April 29th. One analyst has rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $71.36.
NASDAQ IART traded down $0.11 during trading hours on Thursday, hitting $73.95. 331,093 shares of the company’s stock were exchanged, compared to its average volume of 382,011. The business’s 50 day moving average is $70.23 and its 200-day moving average is $63.40. Integra LifeSciences has a 12-month low of $42.12 and a 12-month high of $77.40. The firm has a market capitalization of $6.25 billion, a P/E ratio of 110.54, a price-to-earnings-growth ratio of 1.97 and a beta of 1.26. The company has a debt-to-equity ratio of 1.08, a quick ratio of 3.31 and a current ratio of 4.52.
In other Integra LifeSciences news, COO Glenn Coleman sold 25,658 shares of the firm’s stock in a transaction that occurred on Friday, April 16th. The stock was sold at an average price of $71.50, for a total transaction of $1,834,547.00. Following the completion of the sale, the chief operating officer now owns 57,714 shares in the company, valued at approximately $4,126,551. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Tru St Partnership, L.P. sold 70,275 shares of the firm’s stock in a transaction that occurred on Thursday, February 18th. The shares were sold at an average price of $71.15, for a total value of $5,000,066.25. Following the sale, the insider now owns 9,820,930 shares of the company’s stock, valued at approximately $698,759,169.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,086,352 shares of company stock valued at $74,379,561. Insiders own 4.30% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of IART. Eaton Vance Management grew its stake in Integra LifeSciences by 46.8% during the 4th quarter. Eaton Vance Management now owns 2,487,433 shares of the life sciences company’s stock valued at $161,484,000 after purchasing an additional 792,588 shares in the last quarter. Norges Bank acquired a new position in shares of Integra LifeSciences in the 4th quarter worth approximately $46,303,000. Janus Henderson Group PLC grew its position in shares of Integra LifeSciences by 14.1% in the 4th quarter. Janus Henderson Group PLC now owns 4,622,163 shares of the life sciences company’s stock worth $300,071,000 after acquiring an additional 572,291 shares in the last quarter. Cooke & Bieler LP grew its position in shares of Integra LifeSciences by 9.9% in the 4th quarter. Cooke & Bieler LP now owns 2,710,733 shares of the life sciences company’s stock worth $175,981,000 after acquiring an additional 244,503 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. grew its position in shares of Integra LifeSciences by 263.5% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 284,545 shares of the life sciences company’s stock worth $18,473,000 after acquiring an additional 206,260 shares in the last quarter. Hedge funds and other institutional investors own 85.71% of the company’s stock.
Integra LifeSciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Featured Article: Monthly Dividend Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.